 Kathryn Bowman
Concepts (89)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Fc | 2 | 2023 | 55 | 0.850 |
Why?
| | Antibodies | 2 | 2023 | 407 | 0.760 |
Why?
| | Viral Vaccines | 1 | 2022 | 107 | 0.700 |
Why?
| | Tuberculosis | 3 | 2024 | 280 | 0.440 |
Why?
| | Mycobacterium tuberculosis | 3 | 2024 | 317 | 0.440 |
Why?
| | Immunity, Humoral | 4 | 2022 | 117 | 0.410 |
Why?
| | Spike Glycoprotein, Coronavirus | 4 | 2022 | 118 | 0.300 |
Why?
| | Antibodies, Viral | 4 | 2022 | 649 | 0.240 |
Why?
| | Antibodies, Neutralizing | 3 | 2022 | 302 | 0.230 |
Why?
| | Immunoglobulin Isotypes | 1 | 2023 | 36 | 0.210 |
Why?
| | Antibodies, Bacterial | 1 | 2024 | 146 | 0.200 |
Why?
| | Immunity | 1 | 2023 | 141 | 0.200 |
Why?
| | Saponins | 1 | 2021 | 9 | 0.180 |
Why?
| | Cross Reactions | 1 | 2021 | 130 | 0.180 |
Why?
| | Disease Progression | 3 | 2024 | 2734 | 0.180 |
Why?
| | Protein Processing, Post-Translational | 1 | 2023 | 463 | 0.170 |
Why?
| | Receptors, Interleukin-6 | 1 | 2020 | 46 | 0.170 |
Why?
| | Antiphospholipid Syndrome | 1 | 2020 | 33 | 0.160 |
Why?
| | Immunocompromised Host | 1 | 2020 | 207 | 0.150 |
Why?
| | Toll-Like Receptor 2 | 1 | 2018 | 116 | 0.140 |
Why?
| | Vaccination | 3 | 2022 | 1435 | 0.140 |
Why?
| | Interleukin-2 | 1 | 2018 | 451 | 0.130 |
Why?
| | Membrane Glycoproteins | 1 | 2018 | 500 | 0.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 817 | 0.110 |
Why?
| | RNA, Messenger | 1 | 2022 | 2817 | 0.110 |
Why?
| | HIV Infections | 2 | 2023 | 2944 | 0.100 |
Why?
| | South Africa | 2 | 2024 | 229 | 0.100 |
Why?
| | AIDS Vaccines | 1 | 2013 | 53 | 0.100 |
Why?
| | HIV | 1 | 2013 | 246 | 0.090 |
Why?
| | Macaca mulatta | 2 | 2022 | 185 | 0.090 |
Why?
| | T-Lymphocyte Subsets | 1 | 2013 | 417 | 0.080 |
Why?
| | CD4 Lymphocyte Count | 2 | 2023 | 280 | 0.070 |
Why?
| | Humans | 11 | 2024 | 138651 | 0.060 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2013 | 1101 | 0.060 |
Why?
| | Viral Load | 2 | 2020 | 500 | 0.060 |
Why?
| | Antibody Formation | 1 | 2024 | 299 | 0.050 |
Why?
| | Double-Blind Method | 2 | 2020 | 1946 | 0.050 |
Why?
| | Cohort Studies | 2 | 2024 | 5729 | 0.050 |
Why?
| | Coronavirus OC43, Human | 1 | 2021 | 6 | 0.050 |
Why?
| | Immunoglobulin Class Switching | 1 | 2021 | 21 | 0.050 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2021 | 85 | 0.050 |
Why?
| | Immunogenicity, Vaccine | 1 | 2021 | 34 | 0.040 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2021 | 60 | 0.040 |
Why?
| | Young Adult | 3 | 2024 | 13322 | 0.040 |
Why?
| | Immunoglobulin Fc Fragments | 1 | 2021 | 43 | 0.040 |
Why?
| | Viremia | 1 | 2022 | 152 | 0.040 |
Why?
| | Intubation | 1 | 2020 | 6 | 0.040 |
Why?
| | Respiratory Therapy | 1 | 2020 | 25 | 0.040 |
Why?
| | Boston | 1 | 2020 | 93 | 0.040 |
Why?
| | Primates | 1 | 2021 | 138 | 0.040 |
Why?
| | Fatal Outcome | 1 | 2020 | 311 | 0.040 |
Why?
| | Male | 6 | 2024 | 68216 | 0.040 |
Why?
| | Treatment Failure | 1 | 2020 | 350 | 0.040 |
Why?
| | Interferon-gamma | 1 | 2023 | 789 | 0.040 |
Why?
| | Mycobacterium bovis | 1 | 2018 | 17 | 0.040 |
Why?
| | Kinetics | 1 | 2022 | 1654 | 0.040 |
Why?
| | Sex Factors | 1 | 2024 | 2058 | 0.040 |
Why?
| | Gene Editing | 1 | 2018 | 84 | 0.030 |
Why?
| | Survivors | 1 | 2021 | 500 | 0.030 |
Why?
| | Adult | 4 | 2024 | 38296 | 0.030 |
Why?
| | Myeloid Cells | 1 | 2018 | 151 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2022 | 903 | 0.030 |
Why?
| | Haplotypes | 1 | 2018 | 494 | 0.030 |
Why?
| | Age Factors | 1 | 2024 | 3274 | 0.030 |
Why?
| | RNA | 1 | 2023 | 928 | 0.030 |
Why?
| | Nanoparticles | 1 | 2021 | 468 | 0.030 |
Why?
| | Animals | 3 | 2022 | 37309 | 0.030 |
Why?
| | Adolescent | 2 | 2024 | 21528 | 0.030 |
Why?
| | Female | 4 | 2024 | 73913 | 0.030 |
Why?
| | Epitope Mapping | 1 | 2013 | 61 | 0.020 |
Why?
| | Virus Latency | 1 | 2013 | 79 | 0.020 |
Why?
| | Middle Aged | 3 | 2020 | 33792 | 0.020 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2013 | 174 | 0.020 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2013 | 184 | 0.020 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2013 | 281 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2018 | 2143 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2018 | 1983 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2368 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2013 | 1358 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2018 | 2602 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2013 | 2162 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2020 | 7683 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2013 | 2928 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2013 | 912 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2023 | 15860 | 0.010 |
Why?
| | Infant | 1 | 2018 | 9565 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2013 | 5160 | 0.010 |
Why?
| | Mice | 1 | 2018 | 17848 | 0.010 |
Why?
| | Aged | 1 | 2020 | 24182 | 0.010 |
Why?
|
|
Bowman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|